Trial Profile

A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 09 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Nov 2025 According to a CytoDyn media release, company will present a poster at the prestigious San Antonio Breast Cancer Symposium (SABCS), being held December 9-12, 2025, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
06 Oct 2025 Status changed from active, no longer recruiting to discontinued.
01 Jul 2025 According to CytoDyn media release, data from a retrospective analysis of this study along with NCT04313075 and NCT04504942, was presented at the 2025 ESMO Breast Cancer meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com